Source comparison
Comparison Table: Tesamorelin + Ipamorelin Blend vs Alternatives
Researchers designing body composition protocols often compare the tesamorelin + ipamorelin blend body composition optimization against other peptide combinations or single-agent approaches. This table outlines mechanism, evidence strength, and practical consi
This comparison does not assign a generated winner or score.
- Researchers designing body composition protocols often compare the tesamorelin + ipamorelin blend body composition optimization against other peptide combinations or single-agent approaches. This table outlines mechanism, evidence strength, and practical considerations.
- | Protocol | Mechanism of Action | Published Evidence | Typical Dosing | Visceral Fat Specificity | Lean Mass Preservation | Bottom Line ||—|—|—|—|—|—|| Tesamorelin + Ipamorelin | Dual pathway: GHRH receptor + ghrelin receptor agonism | Tesamorelin: Phase 3 RCT (15.2% visceral fat ↓). Ipamorelin: preclinical + PK studies | Tesamorelin 1–2mg/day + Ipamorelin 200–300mcg BID | High (tesamorelin targets visceral adipocytes preferentially) | High (ipamorelin stimulates GH without cortisol elevation) | Best-supported combination for visceral fat reduction with lean mass retention; requires daily dosing and cold storage || CJC-1295 + Ipamorelin | GHRH analogue (extended half-life) + ghrelin agonist | CJC-1295: limited human data, mostly veterinary. Ipamorelin: same as above | CJC-1295 1–2mg 2×/week + Ipamorelin 200–300mcg BID | Moderate (CJC-1295 lacks visceral specificity data) | Moderate to high (same ipamorelin benefit) | Lower dosing frequency due to CJC-1295 half-life (6–8 days), but les
- The tesamorelin + ipamorelin blend body composition optimization combines the strongest clinical evidence (tesamorelin's Phase 3 visceral fat data) with the cleanest pharmacological profile (ipamorelin's selectivity). For research models prioritizing visceral adipose reduction without metabolic side effects, it outperforms alternatives.